ADRB2 and Hyperglycemia: The beneficial effects described above are not obvious, since it is an accepted fact that β2-AR agonists administered acutely cause hyperglycaemia (due to enhanced glucose output from the liver) and hyperinsulinaemia in humans and rodents [7–10] and have even been proposed for treatment of hypoglycaemic incidents [11, 12].